Skip to main content
Log in

Prostate-specific antigen density: The role in benign prostate hyperplasia, prostate intraepithelial neoplasm, organ-confined prostate carcinoma and advanced prostate carcinoma

  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

To determine the relative role of prostate-specific antigen density (PSAD) in the early detection of prostate cancer and to assess the hypothesis that PSAD offers significant advantages over prostate-specific antigen (PSA) alone in the evaluation of patients with benign (BPH), pre-malignant (PIN) and malignant prostatic diseases, we studied retrospectively 149 patients who were evaluated with either prostatic biopsies or by surgical means. Mean PSAD was calculated to be 0.1 for BPH patients; 0.09 for PIN-1 patients; 0.1 for PIN-2 patients; 0.51 for organ-confined prostatic carcinoma (CaP) patients and 1.7 for advanced CaP patients. Although we could not be able to differentiate BPH from PIN-1 and PIN-2 by using PSAD alone (p>0.05), there were statistically significant differences between BPH versus localized CaP, PIN-2 versus localized CaP and localized CaP versus advanced CaP (p<0.05). In conclusion we suggest that the information provided by PSAD is superior to absolute PSA values in the differentiation between BPH and CaP but PSAD was not able to add more information on differentiating BPH from pre-malignant conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wang, M. C., Valenzuela, L. A., Murphy, G. P., Chu, T. M.: Purification of a human prostate specific antigen.Invest. Urol., 17, 159 (1979).

    PubMed  CAS  Google Scholar 

  2. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S., Redwine, E.: Prostate specific antigen as a serum marker for adenocarcinoma of the prostate.N. Engl. J. Med., 317, 909 (1987).

    Article  PubMed  CAS  Google Scholar 

  3. Ronnett, B. M., Carmichael, M. J., Carter, H. B., Epstein, J. I.: Does high grade prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels?J. Urol., 150, 386 (1993).

    PubMed  CAS  Google Scholar 

  4. Benson, M. C., Whang, I. S., Pantuck, A., Ring, K., Kaplan, S. A., Olsson, C. A., Cooner, W. H.: Prostate specific antigen density: A means of distinguishing benign prostatic hypertrophy and prostate cancer.J. Urol., 147, 815 (1992).

    PubMed  CAS  Google Scholar 

  5. Ramon, J., Boccon, G. L., Billebaud, T., Asteir, L., Kobelinsky, M., Meulemans, A., Dauge, M. C., Villers, A.: Prostate specific antigen density: A means to enhance detection of prostate cancer.Eur. Urol., 25, 288 (1994).

    PubMed  CAS  Google Scholar 

  6. Wolff, J. M., Scholz, A., Boeckmann, W., Jakse, G.: Differentiation of benign prostatic hyperplasia and prostate cancer employing prostatic specific antigen density.Eur. Urol., 25, 295 (1994).

    PubMed  CAS  Google Scholar 

  7. Akda§, A., Dillioĝlugil, Ö., Çevik, I., Ilker, Y.: Impact of prostate specific antigen in benign prostatic hyperplasia and prostate carcinoma. Preliminary results.Eur. Urol., 25, 299 (1994).

    Google Scholar 

  8. Seaman, E., Whang, M., Olsson, C. A., Katz, A., Cooner, W. H., Benson, M. C.: PSA density (PSAD): Role in patient evaluation and management.Urol. Clin. North. Am., 20, 653 (1993).

    PubMed  CAS  Google Scholar 

  9. Rommel, M. F., Agusta, V. E., Breslin, J. A., Huffnagel, H. W., Pohl, E. C., Sieber, P. R., Stahl, C. A.: The use of prostate specific antigen and prostate specific antigen density in the diagnosis of prostate cancer in a community based urology practice.J. Urol., 151, 88 (1994)

    PubMed  CAS  Google Scholar 

  10. Shinohara, K., Wolf, J. S., Narayan, P., Carroll, P. R.: Comparison of prostatic specific antigen density for 3 clinical applications.J. Urol., 152, 120 (1994).

    PubMed  CAS  Google Scholar 

  11. Partin, A. W., Yoo, J. H., Carter, B., Pearson, J. D., Chan, D. W., Epstein, J. I., Walsh, P. C.: The use of prostate specific antigen, clinical state and Gleason score to predict pathological stage in men with localized prostate cancer.J. Urol., 150, 110 (1993).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

I§ikay, L., Yaman, Ö., Bozlu, M. et al. Prostate-specific antigen density: The role in benign prostate hyperplasia, prostate intraepithelial neoplasm, organ-confined prostate carcinoma and advanced prostate carcinoma. International Urology and Nephrology 27, 757–761 (1995). https://doi.org/10.1007/BF02552143

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02552143

Keywords

Navigation